Company: REVB
Filing Date: 2025-09-30
Form Type: S-3/A
Source: 0001193125-25-223617
Chunk: 5

Company: REVELATION BIOSCIENCES, INC.
Filing Date: 2025-09-30
Form: S-3/A
Chunk 5
---
 of clinical data; the outcome of the clinical data, including whether the results of such study is positive or whether it can be replicated; the outcome of data collected, including whether the results of such data and/or correlation can be replicated; the timing, costs, conduct and outcome of our other clinical studies; the anticipated treatment of future clinical data by the FDA, the EMA or other regulatory authorities, including whether such data will be sufficient for approval; the success of future development activities for its product candidates; potential indications for which product candidates may be developed; the potential impact that global health crises may have on Revelation’s suppliers, vendors, regulatory agencies, employees and the global economy as a whole; the ability of Revelation to maintain the listing of its securities on The Nasdaq Stock Market, LLC (“Nasdaq”); the expected duration over which Revelation’s balances will fund its operations; and other risks and uncertainties described herein, as well as those risks and uncertainties discussed from time to time in other reports and other public filings with the SEC by Revelation.

<div align='center'>2</div>

PROSPECTUS SUMMARY This summary description about us and our business highlights selected information contained elsewhere in this prospectus. To understand this offering fully, you should read carefully the entire prospectus, including “Risk Factors” and “Special Note Regarding Forward-Looking Statements.” Unless the context indicates or suggests otherwise, references to “we,” “our,” “us,” the “Company,” or the “Registrant” refer to Revelation Biosciences, Inc., a Delaware corporation, and its subsidiary. ABOUT THE COMPANY Revelation is a clinical-stage biopharmaceutical company founded in November 2019. We are focused on the development or commercialization of products that focused on rebalancing inflammation. We are developing a pipeline of potential high-value products based on Gemini. Gemini is our proprietary formulation of phosphorylated hexaacyl disaccharide (PHAD ® ) an established TLR4 agonist that can stimulate the human body’s innate immune response to prevent and treat disease. The product candidates being developed by us are based on our proprietary Gemini formulation of PHAD. Our current Gemini based programs consist of: Gemini-PSI, which is being developed for the prevention of post surgical infection (PSI); Gemini-AKI, which is being developed for the prevention of acute kidney injury (AKI); and Gemini-CKD for the treatment of chronic kidney disease (CKD). In September of 2025 we announced positive results from the PRIME Phase